Why Legendary?

• Legendary Seeds have already obtained the ICA’s licenses, including the Selected Seed Producer (This is no longer issued by the government, limited companies in Colombia) 
• We own 676 genetics certified at the ICA, with 440 being THC dominant. The number of companies with this License is limited as the application to become on closed on December 31, 2018
• Intellectual property protection by direct contract with owners of the genetics
• 25 hectares of agricultural land
• We are located in one of the safest regions in the country, close to both Police and Military stations

• Quality control and quality assurance, our team is built around top professionals in the field
• Signed agreement with Universidad Del Norte to collaborate in the research and investigation on cannabis, its derivatives and by products
• Agreement is in place with Colkannab, an already operating cannabis company located in Villavicencio, to register and certify all of our genetics in both sub-regions. Both companies own more than 600 genetics certified at the ICA​

Why Colombia?

Taking into account how the global cannabis industry is evolving, events such as the UN accepting the OMS’s recommendations by removing cannabis (and resin) from the Schedule IV classification and acknowledging its medicinal value, the House of Representatives’ historic pass on the MORE act and the current wave of cannabis legalization through the globe raises awareness on the subject and to lowers the remaining commercial and financial barriers for the global cannabis industry and its participants. For this, Colombia plays an important role because of:

• Our extensive experience in the Flower Industry
• Our strategic location for international distribution 
• One of the most advanced cannabis regulatory frameworks in the world
• Low production costs 
• Excellent natural conditions for a year-round cultivation system

On the other hand, Colombia has become one of the first countries to extend national health insurance for patients to include medicinal cannabis as a first line therapy.